DIECI, MARIA VITTORIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.480
AS - Asia 931
EU - Europa 908
SA - Sud America 8
AF - Africa 6
OC - Oceania 2
Totale 9.335
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.469
CN - Cina 460
IT - Italia 405
SG - Singapore 355
FI - Finlandia 130
SE - Svezia 112
FR - Francia 74
GB - Regno Unito 71
IN - India 52
DE - Germania 51
HK - Hong Kong 30
IE - Irlanda 16
CA - Canada 11
CZ - Repubblica Ceca 10
VN - Vietnam 10
PH - Filippine 8
BR - Brasile 7
BE - Belgio 6
ES - Italia 6
NL - Olanda 6
UA - Ucraina 6
MK - Macedonia 5
EG - Egitto 3
JP - Giappone 3
AU - Australia 2
CH - Svizzera 2
IL - Israele 2
IR - Iran 2
MA - Marocco 2
NP - Nepal 2
TR - Turchia 2
AL - Albania 1
DK - Danimarca 1
EC - Ecuador 1
HR - Croazia 1
ID - Indonesia 1
KR - Corea 1
KZ - Kazakistan 1
LV - Lettonia 1
MY - Malesia 1
OM - Oman 1
PT - Portogallo 1
RO - Romania 1
RU - Federazione Russa 1
SC - Seychelles 1
SI - Slovenia 1
Totale 9.335
Salva come PNG Salva come JPEG
Città #
Fairfield 1.403
Woodbridge 728
Chandler 655
Ashburn 617
Houston 608
Seattle 478
Ann Arbor 463
Cambridge 461
Wilmington 427
Singapore 280
Boardman 196
Padova 164
San Diego 133
Medford 120
Princeton 120
Beijing 114
Des Moines 90
Helsinki 83
Santa Clara 62
Roxbury 59
Nanjing 57
Pune 35
Milan 32
London 30
Jinan 26
New York 25
Shenyang 22
Guangzhou 20
Rome 19
Nanchang 18
Dublin 16
Dallas 14
Norwalk 14
Falls Church 13
Zhengzhou 12
Hong Kong 11
Codogno 10
Dong Ket 10
Tianjin 10
Changsha 9
Hebei 9
Ningbo 9
Ogden 9
Selvazzano Dentro 9
Chiswick 8
Olomouc 8
Ottawa 8
Hangzhou 7
Jiaxing 7
Lappeenranta 7
Brussels 6
Florence 6
Hefei 6
Los Angeles 6
Redwood City 6
Washington 6
Bologna 5
Haikou 5
Kharkiv 5
Kilburn 5
Paris 5
Skopje 5
Verona 5
Columbus 4
Council Bluffs 4
Hounslow 4
Kunming 4
Naples 4
New Bedfont 4
Rubano 4
Shanghai 4
Tappahannock 4
Todi 4
Turin 4
Vicenza 4
Barcelona 3
Bergamo 3
Falkenstein 3
Hamburg 3
Morgano 3
Palermo 3
Springfield 3
Taizhou 3
Venice 3
Acton 2
Amsterdam 2
Ancona 2
Andrano 2
Ascoli Piceno 2
Avezzano 2
Baotou 2
Borås 2
Bursa 2
Capo d'Orlando 2
Caserta 2
Chicago 2
Chioggia 2
Clermont-Ferrand 2
Fisciano 2
Fort Worth 2
Totale 7.923
Salva come PNG Salva come JPEG
Nome #
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 184
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 175
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers 148
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 147
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 144
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary 141
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 138
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 137
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 131
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 129
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 129
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 127
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 126
Immune characterization of breast cancer metastases: Prognostic implications 124
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 122
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 121
Escalation and de-escalation in HER2 positive early breast cancer 118
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 117
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 115
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials 112
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 109
Electrochemotherapy of superficial tumors – Current status:: Basic principles, operating procedures, shared indications, and emerging applications 107
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. 105
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 103
Olaparib for the treatment of breast cancer 103
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities 102
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 102
Fat grafting for breast cancer patients: From basic science to clinical studies 100
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 98
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis 97
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study 95
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 94
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 94
Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies 93
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 93
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 93
Quantification of residual risk of relapse in breast cancer patients optimally treated 92
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 91
Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers 90
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives 89
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 89
New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer 88
Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives 87
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis 85
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 84
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 84
Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents 83
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. 83
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer 83
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 78
HER2-Positive Early Breast Cancer 78
Timing for starting second line therapy in recurrent ovarian cancer. 77
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 76
PIK3CA: a Target or a Marker in Breast Cancers 75
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 74
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer 73
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 73
Preoperative Carboplatin-Paclitaxel-Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study. 72
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 72
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 71
The Future of Chemotherapy in the Era of Personalized Medicine 70
Landscape and evolution of therapeutic research for breast cancer patients 69
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neo-adjuvant chemotherapy 69
Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM) 69
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy 68
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 68
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 66
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 66
Whole exome sequencing of rare aggressive breast cancer histologies 65
Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 63
GD2 expression in breast cancer 63
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 63
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 62
Evolution of HER2-low expression from primary to recurrent breast cancer 62
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 60
Erbb2 mrna expression and response to ado-trastuzumab emtansine (T-dm1) in her2-positive breast cancer 60
Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer 58
186O Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial 57
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study [Ann Oncol, 25, (2015) 611-618] DOI: 10.1093/annonc/mdt556 56
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases 56
Clinical development of mTOR inhibitors in breast cancer 55
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype 55
Solitary biceps muscle metastasis from neuroendocrine breast tumor 55
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 53
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors 52
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 52
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy 51
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 49
Pregnancy after breast cancer in patients with germline BRCA mutations 48
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 48
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 45
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy 44
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials 44
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 43
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice 42
Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center 42
Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review 42
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 42
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 40
Targeting the Fibroblast Growth Factor Receptor Pathway in Human Cancer 40
Totale 8.432
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.988
article - articoli 42.133
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 630
Totale 85.751
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.411 0 0 0 0 175 102 181 205 269 276 124 79
2020/20211.585 57 111 61 102 70 228 97 126 183 284 177 89
2021/20221.804 109 181 178 97 185 125 150 141 98 70 130 340
2022/20231.310 268 150 53 169 155 146 28 79 160 15 65 22
2023/2024892 79 96 97 62 60 112 69 40 25 49 87 116
2024/2025800 12 259 135 129 265 0 0 0 0 0 0 0
Totale 9.613